News & Media
Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Torezolid Phase 1 Clinical Trial Results Disclosed
PDF Version Available (112kb)
San Diego, CA, October 20, 2008 – Trius Therapeutics, Inc., a biopharmaceutical company developing “Best-in-Class” drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead program, Torezolid, and its other pipeline programs will be presented in eighteen presentations at the upcoming joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) meeting in Washington, DC. Thirteen of the presentations focus on Torezolid, a second generation oxazolidinone that recently commenced Phase 2 clinical studies.
"Acceptance of these presentations by the ICAAC committee highlights the interest in and value of the Torezolid program, the Trius pipeline, and our underlying technologies,” stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are especially pleased to provide details of our Torezolid Phase 1 clinical trial results that support the once-daily dosing and short course of therapy in our recently initiated Phase 2 study in complicated skin and skin structure infections (cSSSIs). It is also exciting to see that the results of studies by external investigators demonstrate the drug’s increased potency and expanded spectrum of activity.”
The presentations are as follows:
Saturday, October 25th
(Poster Summary Session, Ballroom A/B, 10:00 am – 12:00 pm)
- Oral Presentation: Overview of Torezolid and TR-700 Posters and Presentations
(Poster Session 23, 12:15 pm – 1:15 pm)
- F1-334: Discovery and SAR of a Novel Series of Pyrimidine Antibacterials Targeting Methionyl-tRNA Synthase (MetRS)
- F1-335: In Vitro Activity of RX100472 Against Clinically Important Bacteria
- F1-336: Advanced Microbiology Study of Rx100472, A Novel Methionyl-tRNA Synthetase (MetRS) inhibitor
- F1-337: In Vivo Efficacy of Rx100472, A Novel Methionyl-tRNA Synthetase (MetRS) Inhibitor
Sunday, October 26th
(Poster Session 92, 11:15 am – 12:15 pm)
- A-985: Pharmacodynamics of Torezolid in a Mouse Thigh Infection Model Against S. aureus ATCC 33591, a Methicillin-Resistant Isolate
Monday, October 27th
(Poster Session 196, 11:15 am – 12:15 pm)
- F1-2060: MICs of TR-700, the Active Moiety of the Novel Oxazolidinone Prodrug Torezolid, for Linezolid-Susceptible and –Resistant Enterococci and Staphylcocci
- F1-2061: TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-Positive Species with Well-Characterized Resistance Mechanisms
- F1-2062: In Vitro Pharmacodynamics of TR-700, the Active Moiety of Prodrug Torezolid, a Novel Oxazolidinone, in a Kill-Curve Model
- F1-2063: Human Pharmacokinetics of TR-700 after Ascending Single Oral Doses of the Prodrug Torezolid, a Novel Oxazolidinone Antibiotic
- F1-2064: Human Pharmacokinetics of TR-700 after Multiple Oral Doses of 200 and 400 mg of Torezolid, a Novel Oxazolidinone Antibiotic
- F1-2065: In Vitro and In Vivo Efficacy of Torezolid and TR-700 Versus the Linezolid- and Methicillin-Resistant Staphylococcus aureus cfr Strain CM/05
- F1-2066: Demonstration of Torezolid Efficacy in a Mouse Inhalation Anthrax Model
- F1-2067: Absence of a Pressor Response to Oral Tyramine in Conscious Telemeterized Rats Treated with the Novel Oxazolidinone Torezolid: Comparison to Linezolid
- F1-2068: Quality Control Parameters for TR-700 Broth Microdilution Susceptibility Tests
- F1-2069: Relative Potency of TR-700, the Active Moiety of Prodrug Torezolid, Against Selected Bacterial Pathogens and Provisional Disk Test Criteria
- F1-2069a (“Late Breaker”): Hematological Effects of Torezolid, Linezolid and Placebo Administered for 21 Days in Healthy Subjects
(Poster Session 197, 11:15 am – 12:15 pm)
- F2-2070: Structure Guided Design of Pyrimidine Antibacterials Targeting Methionyl-tRNA Synthase (MetRS)
Copies of these posters will be available on the Trius website following the ICAAC/IDSA meeting.
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, Torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox®. Trius has licensed worldwide rights outside of Korea to Torezolid from Dong-A Pharmaceuticals. Trius’ pipeline includes two preclinical programs being developed to treat serious infections including those caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.